Particle-Enhanced Immunoassay for NT-proBNP Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for determining NT-proBNP concentrations are not sufficiently sensitive, often underestimating true levels due to limitations in recognizing both glycosylated and non-glycosylated forms of the peptide.
Innovation Solution
A particle-enhanced immunoassay using antibodies specifically binding to novel regions of NT-proBNP, immobilized on particles, which can detect both glycosylated and non-glycosylated forms with high affinity, allowing for accurate quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional sandwich immunoassays are used for NT-proBNP detection, then the assay structure is simple and easy to manufacture, but the measurement sensitivity is insufficient and cannot accurately detect low concentrations
Solution Approach 1:
The patent embeds immunoparticles (particles coated with capture antibodies) within the immunoassay system. These particles act as nested functional units that concentrate the detection signal. The immunoparticles are suspended in the assay mixture and provide a large surface area for antigen-antibody interactions, thereby amplifying the measurement signal without requiring complex external instrumentation.
Solution Approach 2:
The patent introduces immunoparticles as intermediary elements between the capture antibody and the detected antigen. These particles serve as signal amplifiers that mediate the interaction between the antibody-antigen complex and the detection system. The particles coated with detection antibodies provide enhanced optical properties (light scattering, absorption) that amplify the measurement signal, enabling detection of low NT-proBNP concentrations.
2Measurement precision
If conventional antibodies are used that recognize common epitopes, then the antibody production is straightforward, but the assay cannot distinguish between glycosylated and non-glycosylated NT-proBNP forms, leading to underestimation
Solution Approach 1:
The patent employs antibodies with highly specific local binding characteristics. The capture antibody is designed to bind to a specific epitope region (amino acids 10-50) of NT-proBNP, while the detection antibody binds to a different epitope. This localized specificity ensures that the assay can accurately detect NT-proBNP regardless of glycosylation status at other regions, as the binding sites are strategically positioned to avoid glycosylation interference.
3Measurement precision
If the assay uses traditional detection methods, then the equipment and procedure are simple, but the detection limit is insufficient for low NT-proBNP concentrations
Solution Approach 1:
The patent utilizes optical property changes of immunoparticles as the detection mechanism. The immunoparticles exhibit enhanced light scattering, absorption, or fluorescence properties when bound to the antigen-antibody complex. This optical signal change provides a sensitive and measurable indicator of NT-proBNP concentration, enabling detection at low levels while using relatively simple photometric or nephelometric instrumentation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a more accurate and sensitive measurement of NT-proBNP concentrations, capable of detecting low levels and improving diagnostic accuracy for heart failure assessment.
Implementation Method 1
determining a change in reflectance, scattering or transmittance of the sample wherein said change is indicative of the concentration of NT-proBNP in the sample
Data Source
AI summary
NT-proBNP can be determined in a biological sample using at least one antibody which recognizes an epitope of NT-proBNP in both a glycosylated and non-glycosylated form of NT-proBNP. Said antibody is preferably an isolated polyclonal antibody or a mixture of monoclonal antibodies coated onto a particle, preferably coated onto said particle in a coating ratio of 6-60%, forming a layer or multiple layers of antibodies on said particle. The assay, realized in the form of a nephelometric or turbidimetric assay, can be applied to a wide range of automated clinical analyzers.